Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma

Paiva, Christine; Kurtis, Boaz; Mekki, M.; Newman, Marissa; Singhal, Seema; Lacouture, Mario E.

doi:10.1093/annonc/mdm436

Cited by 7 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1] This pattern is independent of the length of time the lesion has been present and can be demonstrated in lesions of less than 24 h duration. [4][5][6][7][8][9][10][11] A 66-year-old male with an IgG lambda myeloma that progressed despite autologous peripheral blood stem cell transplantation was being treated with bortezomib (1.3 mg/m 2 ) and melphalan (9 mg/m 2 ) according to VISTA protocol (Velcade as Initial Standard Therapy in Multiple Myeloma). [4][5][6][7][8][9][10][11] A 66-year-old male with an IgG lambda myeloma that progressed despite autologous peripheral blood stem cell transplantation was being treated with bortezomib (1.3 mg/m 2 ) and melphalan (9 mg/m 2 ) according to VISTA protocol (Velcade as Initial Standard Therapy in Multiple Myeloma).…”

mentioning

confidence: 99%

Histiocytoid sweet syndrome related to bortezomib: A mimicker of cutaneous infiltration by myeloma

Llamas‐Velasco¹,

Concha-Garzón²,

Fraga³

et al. 2015

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

mentioning

confidence: 99%

Histiocytoid sweet syndrome related to bortezomib: A mimicker of cutaneous infiltration by myeloma

Llamas‐Velasco¹,

Concha-Garzón²,

Fraga³

et al. 2015

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

“…Previous reported cases have determined that dermatosis‐related symptoms, including rash, are not a contraindication for use . Rash is usually resolved with a combination of topical or systemic corticosteroids and antihistamines.…”

Section: Discussionmentioning

confidence: 99%

“…Prevention of rash with rechallenge is typically accomplished either by prophylactic oral prednisone administration or concurrent intravenous corticosteroids, allowing for continuation of bortezomib therapy . If bortezomib is to be administered subcutaneously, the package insert states that development of local injection site reactions can prompt reconstitution to a lower concentration of 1 mg/ml, versus the conventional concentration of 2.5 mg/ml…”

Section: Discussionmentioning

confidence: 99%

Bortezomib‐Induced Sweet's Syndrome Confirmed by Rechallenge

et al. 2013

View full text Add to dashboard Cite

Sweet's syndrome, also known as acute febrile neutrophilic dermatosis, is characterized predominantly by fever, elevated neutrophil count, and erythematous skin lesions composed of plaques and nodules that appear on upper extremities, face, or neck. The incidence of Sweet's syndrome in the general population is unknown due to the rarity of the condition and potential lack of reporting. Bortezomib, an antineoplastic agent that is the standard of care in patients with multiple myeloma, has been reported to be associated with Sweet's syndrome. We describe a 69-year-old man who developed Sweet's syndrome during his initial course (after cycle 4) of bortezomib for treatment of multiple myeloma; he again experienced Sweet's syndrome 3.5 years later when rechallenged with bortezomib (after cycle 5) for treatment of relapsed multiple myeloma. The patient's signs, symptoms, and biopsy results were identical during both presentations of Sweet's syndrome. In both instances, the syndrome spontaneously resolved without incident and without supportive treatment with corticosteroids or antihistamines. To our knowledge, this is the first case report of a patient who developed Sweet's syndrome during an initial course of treatment with bortezomib and after rechallenge with bortezomib for relapsed disease. As proteasome inhibitors continue to be a mainstay of therapy for both treatment and salvage therapy for multiple myeloma, this case demonstrates that rechallenge with bortezomib is an option for patients who develop Sweet's syndrome.

show abstract

“…Éruptions cutanées, prurit, érythème, urticaire, oedème périorbitaire, hypersudation, sécheresse cutanée et eczéma ont été décrits ainsi que, plus rarement, alopécie, troubles des phanères, photosensibilité, dyschromies, voire psoriasis [12][13][14][15][16]. Un syndrome de Sweet n'a été rapporté que chez trois patients porteurs d'un myélome multiple traité par bortezomib : lors de la seconde [17] ou la quatrième injection du deuxième cycle [18], mais aussi dès la première administration chez le troisième patient [18].…”

Section: Discussionunclassified